Health Care & Life Sciences » Pharmaceuticals | Innoviva Inc.

Innoviva Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
170,701.00
168,464.00
18,760.00
59,536.00
134,272.00
406,328
Depreciation, Depletion & Amortization
8,203.00
12,175.00
13,933.00
13,954.00
13,982.00
13,872
Other Funds
36,800.00
277,541.00
-
-
23.00
16,145
Funds from Operations
135,372.00
100,472.00
26,984.00
82,948.00
170,029.00
240,291
Changes in Working Capital
5,770.00
30,251.00
16,853.00
21,964.00
28,280.00
16,760
Net Operating Cash Flow
129,602.00
130,723.00
10,131.00
60,984.00
141,749.00
223,531
Capital Expenditures
87,734.00
135,689.00
7.00
278.00
-
Purchase/Sale of Investments
131,946.00
69,656.00
159,175.00
4,302.00
23,236.00
Net Investing Cash Flow
219,580.00
65,060.00
159,168.00
4,580.00
23,236.00
Cash Dividends Paid - Total
-
56,988.00
87,331.00
960.00
281.00
Issuance/Reduction of Debt, Net
281,622.00
434,677.00
-
18,398.00
63,742.00
Net Financing Cash Flow
397,843.00
149,073.00
106,919.00
97,568.00
163,193.00
Net Change in Cash
48,661.00
46,710.00
62,380.00
41,164.00
44,680.00
Free Cash Flow
132,336.00
131,412.00
10,124.00
60,706.00
141,749.00
Other Sources
100.00
973.00
-
-
-
Change in Capital Stock
153,021.00
48,925.00
19,588.00
78,210.00
99,193.00

About Innoviva

View Profile
Address
2000 Sierra Point Parkway
Brisbane California 94005
United States
Employees -
Website http://www.inva.com
Updated 07/08/2019
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.